Uncategorized
Ocular Therapeutix reports successful topline results in phase 3 trial of Dextenza
A phase 3 clinical trial of Dextenza 0.4 mg for the treatment of post-surgical ocular inflammation and pain has shown positive topline results, according to a press release from Ocular Therapeutix.The double-masked, parallel-arm, randomized study included 438 patients who underwent clear corneal cataract surgery at 21 sites across the United States. The patients received either Dextenza (dexamethasone insert) or a placebo vehicle. Those treated with Dextenza showed “statistically significant differences” in regards to pain and inflammation, according to the release.